Acadia Pharmaceuticals Stock News

Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

During the last session, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)s traded shares were 0.83 million, with the beta value of the company hitting 0.57. At the end of the trading day, the stocks price was $25.86, reflecting an intraday loss of -2.89% or -$0.77. The 52-week high for the ACAD share is $52.12, that puts it down Can ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Still Be Considered A Loss When Its Up 10.80% YTD? Read More »

Acadia Pharmaceuticals (ACAD) resubmitted an application to the U.S

Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) has resubmitted its FDA supplemental marketing application for pimavanserin for hallucinations and delusions associated with Alzheimer''s disease psychosis (ADP). This resubmission responds to the FDA''s Complete Response Letter (CRL) to the … Full story available on Benzinga.com

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at 1:40 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s website, www.acadia-pharm.com, under the investors section and an archived recording will be available on the website through March 18, 2022. About Acadia Phar

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022, at

Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE:FRT) was changed from Equal-Weight to Overweight. Federal Realty Investment earned $1.51 in the third qua

Upgrades According to Capital One, the prior rating for Federal Realty Investment Trust (NYSE: FRT ) was changed from Equal-Weight to Overweight. Federal Realty Investment earned $1.51 in the third quarter, compared to $1.12 in the year-ago quarter. At the moment, the stock has a 52-week-high of $140.51 and a 52-week-low of $90.16. Federal Realty Investment closed at $122.79 at the end of the last trading period. Check out this: Executives Buy Around $64M Of 3 Stocks According to SVB Leerink, the prior rating for Tenet Healthcare Corp (NYSE: THC ) was changed from Market Perform to Outperform. In the fourth quarter, Tenet Healthcare showed an EPS of $2.70, compared to $4.72 from the year-ago quarter. The stock has a 52-week-high of $83.69 and a 52-week-low of $48.20. At the end of the last trading period, Tenet Healthcare closed at $74.07. For Absolute Software Corp (NASDAQ: ABST ), TD Securities upgraded the previous rating of Hold to Buy. Absolute Software earned $0.13 in the second quarter, compared to $0.04 in the year-ago quarter.

ACADIA Pharmaceuticals (NASDAQ: ACAD ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 4 10 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 2 4 0 0 3M Ago 0 2 6 0 0 In the last 3 months, 16 analysts have offered 12-month price targets for ACADIA Pharmaceuticals. The company has an average price target of $30.75 with a high of $42.00 and a low of $23.00. Below is a summary of how these 16 analysts rated ACADIA Pharmaceuticals over the past 3 months. The greater the number of bullish ratings, the more … Full story available on Benzinga.com

Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.

Phillips (PHG) integrates AI and 3D mapping capabilities it its Mobile C-Arm System, Zenition, enhancing its diagnostic imaging portfolio.

Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise

Acadia's (ACAD) Nuplazid, approved for treating hallucinations and delusions associated with Parkinson's disease psychosis, has seen strong uptake so far. Its label expansion studies also hold promise